Cited by 4,319Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and StudiesRenal cell carcinoma treatment

The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Open access

Reig, Maria, Forner, Alejandro, Rimola, Jordi, Ferrer-Fàbrega, Joana, Burrel, Marta, Garcia-Criado, Ángeles, Kelley, Robin K., Galle, Peter R., Mazzaferro, Vincenzo, Salem, Riad, Sangro, Bruno, Singal, Amit G., Vogel, Arndt, Fuster, Josep, Ayuso, Carmen, Bruix, Jordi·2022·Journal of Hepatology

DOI 10.1016/j.jhep.2021.11.018PMC PMC8866082

Open this paper in CoChat — free account Open PDF

Abstract

There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2021.11.018

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citation
Preoperative assessment of liver function: a comparison of 99mTc‐Mebrofenin scintigraphy with indocyanine green clearance test
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citation
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citation
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S. A., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,173
Self-citation
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Hepatocellular carcinoma
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,774
Self-citation
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586

Show all 136 references

Sorted by citations

Items 801–900 of 1,000

Treatment patterns for hepatocellular carcinoma in patients with Child–Pugh class B and their impact on survival: A Korean nationwide registry study
Jeon, D., Song, G., Lee, H. C., & Shim, J. H. (2022) · Liver International · doi:10.1111/liv.15464 · Cited by 13
Identification of a CD4+ conventional T cells-related lncRNAs signature associated with hepatocellular carcinoma prognosis, therapy, and tumor microenvironment
Zhu, L., Zhang, X., Xu, S., Hu, M., Zhao, Z., Zhao, G., Xiao, Z., & Liu, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1111246 · Cited by 13
Transarterial chemoembolization plus immune checkpoint inhibitor as postoperative adjuvant therapy for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter cohort study
Yuan, L.-Y., Feng, J.-K., Zhang, Y., Lu, C., Xu, L., Liang, C., Liu, Z., Mao, F., Xiang, Y., Wang, W., et al. (2023) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2023.01.020 · Cited by 13
Systemic therapy in advanced hepatocellular carcinoma
Ahn, J. C., Tran, N. H., & Yang, J. D. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0051 · Cited by 14
Slow skeletal muscle troponin T acts as a potential prognostic biomarker and therapeutic target for hepatocellular carcinoma
Huang, S., Huang, C., Ko, C., Huang, C.-Y., Liu, S.-H., Lee, Y., Chen, T., Hsueh, C.-W., Tzou, S., Tai, M., et al. (2023) · Gene · doi:10.1016/j.gene.2023.147331 · Cited by 14
Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma
Giovannini, C., Suzzi, F., Tovoli, F., Bruccoleri, M., Marseglia, M., Alimenti, E., Fornari, F., Iavarone, M. A., Piscaglia, F., & Gramantieri, L. (2023) · Cancers · doi:10.3390/cancers15061661 · Cited by 13
“Thirty-eight patients with intermediate or advanced HCC (BCLC B and C) according to the BCLC staging system [20] not amenable to potentially curative treatments or TACE were screened, and four of them did not receive the indication for the atezolizumab–bevacizumab treatment due to ongoing anticoagulant treatment (one…”
Background
Prevalence and Effect of Low Skeletal Muscle Mass among Hepatocellular Carcinoma Patients Undergoing Systemic Therapy: A Systematic Review and Meta-Analysis
Kuo, M., Tseng, C., Hsu, C., Chen, Y., Kao, I.-T., Wu, C., & Shao, S. (2023) · Cancers · doi:10.3390/cancers15092426 · Cited by 13
“survival time for advanced HCC patients [4].”
BackgroundInfluential
Impact of CXCR4-Directed PET/CT on Staging and Proposed Oncologic Management in Patients With Digestive System Tumors
Weich, A., Serfling, S. E., Schlötelburg, W., Higuchi, T., Hartrampf, P. E., Schirbel, A., Heinrich, M., Buck, A. K., Rowe, S. P., Kosmala, A., et al. (2023) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004674 · Cited by 13
Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma
Kawamura, Y., Akuta, N., Shindoh, J., Matsumura, M., Okubo, S., Tominaga, L., Fujiyama, S., Hosaka, T., Saitoh, S., Sezaki, H., et al. (2023) · Cancers · doi:10.3390/cancers15153789 · Cited by 13
Efficacy and safety of transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors in the treatment of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Liu, J., Wei, S., Yang, L., Yu, J., Duan, Y., & Yi, P. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05231-x · Cited by 13
“For patients with unresectable HCC (uHCC), systematic therapies are presently regarded as the primary treatment option conferring real survival benefits (Reig et al. 2022).”
Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Liu, J., Yang, L., Song, W., Li, J., & Yi, P. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05342-5 · Cited by 13
“For those patients with unresectable HCC (uHCC), systematic therapies are regarded as presently primary treatment which can confer real survival benefits (Reig et al. 2022).”
Background
The Negative Impact of Sarcopenia on Hepatocellular Carcinoma Treatment Outcomes
Cespiati, A., Smith, D., Lombardi, R., & Fracanzani, A. L. (2024) · Cancers · doi:10.3390/cancers16132315 · Cited by 12
The Evolving Role of Imaging in Hepatocellular Carcinoma: From Pathomolecular Profiling to Prognostic Decision-Making
Jiang, H., Wei, H., Liang, L., Wang, Y., Kuang, M., Ronot, M., Song, B., & Lee, J. M. (2025) · Liver Cancer · doi:10.1159/000546966 · Cited by 15
Applications of artificial intelligence in liver cancer: A scoping review
Chierici, A. P., Lareyre, F., Iannelli, A., Salucki, B., Goffart, S., Guzzi, L., Poggi, E., Delingette, H., & Raffort, J. (2025) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2025.103244 · Cited by 16
The first full year of histotripsy for liver tumors: Local tumor control and preliminary oncologic efficacy
Wehrle, C. J., Ahmed, A. F. S., Knott, E. A., Hong, H., Uysal, M., Schlegel, A. A., Berber, E., Walsh, R. M., Kim, J., Aucejo, F., et al. (2025) · Surgery · doi:10.1016/j.surg.2025.109898 · Cited by 12
EvoMDT: a self-evolving multi-agent system for structured clinical decision-making in multi-cancer
Liu, Q., Hu, Z., Huang, T., Niu, Y., Zhang, X., Ma, S., Lin, C., Goh, K. H., Kwon, H. E., Gao, F., et al. (2026) · npj Digital Medicine · doi:10.1038/s41746-025-02304-8 · Cited by 18
Animal Models of Hepatocellular Carcinoma for Local-Regional Intraarterial Therapies
Chandra, V., Wilkins, L. R., & Brautigan, D. L. (2022) · Radiology Imaging Cancer · doi:10.1148/rycan.210098 · Cited by 12
Selective internal radiation therapy for hepatocellular carcinoma: A 15‐year multicenter Australian cohort study
Prince, D. S., Schlaphoff, G., Davison, S. A., Huo, Y. R., Xiang, H., Chan, M. V., Lee, A. U., Thailakanathan, C., Jebeili, H., Rogan, C., et al. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15986 · Cited by 12
Microballoon Interventions for Liver Tumors: Review of Literature and Future Perspectives
Lucatelli, P., Rocco, B., Ciaglia, S., Damato, E., Mosconi, C., Argirò, R., & Catalano, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185334 · Cited by 13
Programmed cell death protein 1 and tyrosine kinase inhibition plus transcatheter arterial chemoembolization of advanced hepatocellular carcinoma
Peng, W. J., Zhang, X., Li, C., Zhu, X., Li, Q., Chen, W., Lu, W., Liu, C., Zhou, Y., Shi, Y., et al. (2022) · British journal of surgery · doi:10.1093/bjs/znac334 · Cited by 12
The regulation and functions of ACSL3 and ACSL4 in the liver and hepatocellular carcinoma
Liu, J. Y., & Waugh, M. G. (2022) · Liver Cancer International · doi:10.1002/lci2.68 · Cited by 12
Maximum tumor-absorbed dose measured by voxel-based multicompartmental dosimetry as a response predictor in yttrium-90 radiation segmentectomy for hepatocellular carcinoma
Rincón, J. O., Regi, A. R., Peña, A. M. M., Berenguer, L. R., Leyte, M. G., Martín, L. C., Santa, J. A. G. D. L., Boyra, M. E., Ruiz, C. G., Rodríguez, A. C., et al. (2023) · EJNMMI Physics · doi:10.1186/s40658-022-00520-9 · Cited by 12
“Currently, the technology available in most centers performing TARE, comprising the incorporation of cone beam CT (CBCT), SPECT/CT gamma cameras and the design of dedicated software for voxel-based multicompartment dosimetric analysis, allows for much safer planning of the procedure and the implementation of highly pe…”
BackgroundInfluential
Quantitative Analysis of Signal Heterogeneity in the Hepatobiliary Phase of Pretreatment Gadoxetic Acid-Enhanced MRI as a Prognostic Imaging Biomarker in Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma
Minamiguchi, K., Nishiofuku, H., Saito, N., Sato, T. A., Taiji, R., Matsumoto, T., Maeda, S., Chanoki, Y., Tachiiri, T., Kunichika, H., et al. (2023) · Cancers · doi:10.3390/cancers15041238 · Cited by 12
“According to the latest update of the Barcelona Clinic Liver Cancer (BCLC) guidelines, trans-arterial chemoembolization (TACE) is still reserved and indicated as the first-line treatment for HCC patients at intermediate-stage (BCLC-B) who have well-defined nodules and can be treated by selective catheterization [1].”
Background
Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma
Zhang, Z., Jiao, T., Li, J., Hu, B., Zhang, W., Wang, Z., Wan, T., Wang, Y., & Lu, S. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-02939-5 · Cited by 12
Effect of vessels that encapsulate tumor clusters (VETC) on the prognosis of different stages of hepatocellular carcinoma after hepatectomy
Wang, Y., Dong, K., Wang, K., Sun, Y. L., & Xing, B. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.03.008 · Cited by 11
Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study
Pan, Y., Zhu, X., Liu, J., Zhong, J., Zhang, W., Shen, S., Jin, R., Liu, H., Ye, F., Hu, K., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1138355 · Cited by 12
Dual role of ANGPTL8 in promoting tumor cell proliferation and immune escape during hepatocarcinogenesis
Gao, Y., Yuan, Y., Shu, W., Chen, Y., Zhang, Z., Feng, Y., Jiang, B., Ma, S., Hu, R., Fang, C., et al. (2023) · Oncogenesis · doi:10.1038/s41389-023-00473-3 · Cited by 12
“Even with the development of advanced diagnostic and therapeutic strategies for HCC, the prognosis for patients with HCC remains poor owing to its complex and multifaceted molecular pathogenesis [2].”
Background
A Novel Nomogram for Predicting the Overall Survival in Patients with Unresectable HCC after TACE plus Hepatic Arterial Infusion Chemotherapy
Liu, B., Gao, S., Guo, J., Kou, F., Liu, S., Zhang, X., Wang, X., Cao, G., Chen, H., Liu, P., et al. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101705 · Cited by 12
Glutamine synthetase-negative hepatocellular carcinoma has better prognosis and response to sorafenib treatment after hepatectomy
Shao, M., Tao, Q., Xu, Y., Xu, Q. R., Shu, Y., Chen, Y., Shen, J., Zhou, Y., Wu, Z., Chen, M., et al. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002380 · Cited by 14
The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Treating Portal Hypertension in Patients with Hepatocellular Carcinoma
Balducci, D., Montori, M., BLASIO, F. D., Bucchianico, A. D., Argenziano, M. E., Svegliati‐Baroni, G., & Scarpellini, E. (2023) · Medicina · doi:10.3390/medicina59061150 · Cited by 12
“Interestingly, the modified step-by-step approach may shorten the distance between BCLC-C and BCLC-D due to CSPH and may extend survival time of patients (from 3 months to 2 years) [11].”
BackgroundInfluential
Clinical Significance of Non-Coding RNA Regulation of Programmed Cell Death in Hepatocellular Carcinoma
Chen, W., Ruan, M., Zou, M., Liu, F., & Liu, H. (2023) · Cancers · doi:10.3390/cancers15164187 · Cited by 12
“Meanwhile, extensively utilized in Asia, hepatic artery infusion chemotherapy has been incorporated into treatment guidelines in Japan and South Korea [131,132].”
Background
Imaging prognostication and tumor biology in hepatocellular carcinoma
Kadi, D., Yamamoto, M., Lerner, E., Jiang, H., Fowler, K. J., & Bashir, M. R. (2023) · Journal of Liver Cancer · doi:10.17998/jlc.2023.08.29 · Cited by 12
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate‐stage hepatocellular carcinoma
Tada, T., Kumada, T., Hiraoka, A., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., et al. (2023) · Liver International · doi:10.1111/liv.15753 · Cited by 12
Clinical Complete Response After Conversion Therapy for Unresectable Hepatocellular Carcinoma: Is Salvage Hepatectomy Necessary?
Wu, J., Wu, J., Liu, D.-Y., Li, H., Zhuang, S.-W., Li, B., Zhou, J., Huang, J., Zhang, Z., Li, S.-Q., et al. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s442341 · Cited by 12
Comparative efficacy and safety of systemic therapy for advanced hepatocellular carcinoma: a systematic review and network meta-analysis
Wu, D., Jia, B., Jia, M., Zhao, H., Zhao, H., & Zhou, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1274754 · Cited by 12
Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Gao, B., Yang, F., Zheng, D., Hu, S., Liu, J., Liu, H., Liu, Y., Liu, L., Wang, R., Zhao, Y., et al. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s443041 · Cited by 12
“2,3 TACE has been established worldwide as the standard local treatment for intermediate and advanced HCC, with an overall objective response rate (ORR) ranging from 30% to 40%.”
Background
Efficacy of Yttrium-90 Transarterial Radioembolisation in Advanced Hepatocellular Carcinoma: An Experience With Hybrid Angio-Computed Tomography and Glass Microspheres
Baloji, A., Kalra, N., Chaluvashetty, S. B., Bhujade, H., Chandel, K., Duseja, A. K., Taneja, S., Gorsi, U., Kumar, R., Singh, H., et al. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2023.101342 · Cited by 12
Novel gene-based therapeutic approaches for the management of hepatic complications in diabetes: Reviewing recent advances
Yan, Q., Li, D., Jia, S., Yang, J., & Ma, J. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108688 · Cited by 13
Phytochemicals as Potential Lead Molecules against Hepatocellular Carcinoma
Rayginia, T. P., Keerthana, C. K., Shifana, S. C., Maria Joy, P., Ajmani, A., & Anto, R. J. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673275501231213063902 · Cited by 12
Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy
Ielasi, L., Stefanini, B., Conti, F., Tonnini, M., Tortora, R., Magini, G. M., Sacco, R., Pressiani, T., Trevisani, F., Foschi, F. G., et al. (2024) · Current Oncology · doi:10.3390/curroncol31010038 · Cited by 12
“In Western countries, the most used staging system is the Barcelona Clinic Liver Cancer (BCLC), which provides an estimation of prognosis and treatment of choice [2].”
BackgroundMethodInfluential
Liver resection versus radiofrequency ablation or trans-arterial chemoembolization for early-stage (BCLC A) oligo-nodular hepatocellular carcinoma: meta-analysis
Romano, P., Busti, M., Billato, I., D’Amico, F., Marchegiani, G., Pelizzaro, F., Vitale, A., & Cillo, U. (2024) · BJS Open · doi:10.1093/bjsopen/zrad158 · Cited by 12
“For all these reasons, the correct expert recommendation for answering the initial PICO cannot be the exclusion of LR as a therapeutic option for these HCC patients, as done in the last BCLC paper 4 .”
Background
Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular Carcinoma
Tojjari, A., Yu, J. B., & Saeed, A. (2024) · Cancers · doi:10.3390/cancers16051058 · Cited by 12
Recommended 10-Year Follow-Up Strategy for Small Hepatocellular Carcinoma After Radiofrequency Ablation: A Cost-Effectiveness Evaluation
Chen, Q., Chen, S., Yi, J., Wang, J.-L., Zhong, S.-X., Jiang, X., Hu, Y. H., Tan, G.-J., Xu, J., Lyu, N., et al. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002774 · Cited by 12
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma
Ohama, H., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Hatanaka, T., Tani, J., Takaguchi, K., Atsukawa, M., Itobayashi, E., et al. (2024) · Cancer Reports · doi:10.1002/cnr2.2042 · Cited by 12
“46,47 The items in the IMABALI-De scoring system, that is, tumor burden, malignant potential, and hepatic reserve function, provide a versatile system that may also be prognostically useful in Dur/Tre treatment cases.”
Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management
Criss, C. R., & Makary, M. S. (2024) · Current Oncology · doi:10.3390/curroncol31040154 · Cited by 12
“Much of the initial literature encompassing locoregional therapies has focused on the treatment of primary liver cancers and has since been established as one of the mainstay treatment approaches according to the Barcelona Clinic Liver Cancer guidelines for treating hepatocellular carcinoma [49,50].”
Background
Diagnostic performance of CT/MRI LI-RADS v2018 in non-cirrhotic steatotic liver disease
Cao, J. J., Shon, A., Yoon, L. S., Kamaya, A., & Tse, J. R. (2024) · European Radiology · doi:10.1007/s00330-024-10846-w · Cited by 12
Long-Term Outcomes of Balloon TACE for HCC: An European Multicentre Single-Arm Retrospective Study
Lucatelli, P., Rocco, B., beare, T. D., Verset, G., Fucilli, F., Damato, E., Paccapelo, A., Braccischi, L., Tomassoni, M. T., Bucalau, A., et al. (2024) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-024-03779-w · Cited by 12
“According to the Barcelona Clinic Liver Cancer (BCLC) 2022 update [1], transarterial chemoembolisation (TACE) is indicated for treating HCC in the intermediate stage and in the earlier stage when potentially curative options are not feasible.”
Method
Single-Session Ablative Transarterial Radioembolization for Patients with Hepatocellular Carcinoma to Streamline Care: An Initial Experience
Berman, Z. T., Pianka, K. T., Qaseem, Y., Redmond, J. W., & Minocha, J. (2024) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-024-03799-6 · Cited by 12
“With the reduction in resources needed for additional room availability to perform a MAA procedure, more patients are able to be treated, which is especially important now that TARE has been incorporated into the BCLC treatment guidelines and is therefore likely to be used more frequently [2].”
Clinical Results of Holmium-166 Radioembolization with Personalized Dosimetry for the Treatment of Hepatocellular Carcinoma
Kühnel, C., Köhler, A., Brachwitz, T., Seifert, P., Gühne, F., Aschenbach, R., Freudenberg, R., Freesmeyer, M. G., & Drescher, R. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14070747 · Cited by 12
“Since most HCC cases are diagnosed at a multifocal, non-metastatic stage (AJCC stage II/III, BCLC score A/B), TARE is often used as a ﬁrst-line therapy [18].”
Background
Liver resection and transplantation in the era of checkpoint inhibitors
Tabrizian, P., Marino, R., & Chow, P. K. H. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101181 · Cited by 15
“2,15 Randomised trials are ongoing to explore the potential application of combining LRT with ICIs, as new hopes to enhance their ef ﬁ cacy are based on the hypothesised synergistic effect of LRT and ICIs.”
Efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials
Lu, F., Zhao, K., Ye, M.-Q., Xing, G., Liu, B., Li, X.-B., Ran, Y., Wu, F., Chen, W., & Hu, S.-P. (2024) · BMC Cancer · doi:10.1186/s12885-024-12780-y · Cited by 12
“Primary treatments for early-stage HCC include liver resection, transplantation, and radiofrequency ablation [3].”
Background
Heterogeneity in adverse events related to atezolizumab-bevacizumab for hepatocellular carcinoma reported in real-world studies
Campani, C., Pallas, D., Sidali, S., Γιουλεμέ, Ό., Blaise, L., Grando, V., Nkontchou, G., Demory, A., Nahon, P., Ganne‐Carrié, N., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101190 · Cited by 12
A classification model for resectability in hepatocellular carcinoma patients
Nakamura, I., Yoh, T., Nishimura, T., Okuno, M., Okamoto, T., Sueoka, H., Iida, K., Tada, M., Ishii, T., Seo, S., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14108 · Cited by 12
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study
Persano, M., Gardini, A. C., Tada, T., Suda, G., Shimose, S., Kudo, M., Rossari, F., Yoo, C., Cheon, J., Finkelmeier, F., et al. (2024) · Oncology · doi:10.1159/000541018 · Cited by 12
Impact of racial, ethnic, and socioeconomic disparities on presentation and survival of HCC: A multicenter study
Rich, N. E., Jones, P. D., Zhu, H., Prasad, T., Hughes, A. E., Pruitt, S. L., Murphy, C. C., Dahan, K. S. E., Daher, D., Figueroa, G., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000477 · Cited by 12
“[16] Because BCLC stage A patients with large unifocal tumors are often not amenable to curative treatment, we also conducted a sensitivity analysis using Milan Criteria to define early-stage HCC. Univariable and multivariable logistic regression defined factors associated with early-stage HCC…”
MethodSelf-citation
Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma
Hao, K., Paik, A. J., Han, L. H., & Makary, M. S. (2024) · World Journal of Radiology · doi:10.4329/wjr.v16.i10.512 · Cited by 12
Predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma: nomograms based on deep learning analysis of gadoxetic acid-enhanced MRI
Jeong, B., Heo, S., Lee, S. S., Kim, S., Shin, Y. M., Kim, K. M., Ha, T., & Jung, D. (2024) · European Radiology · doi:10.1007/s00330-024-11173-w · Cited by 12
Comparative Outcome Analysis of Lenvatinib Versus Sorafenib for Recurrence of Hepatocellular Carcinoma After Liver Transplantation
Magyar, C. T. J., Perera, S., Rajendran, L., Li, Z., Almugbel, F. A., Feng, S., Choi, W. J., Aceituno, L., Vogel, A., Grant, R. C., et al. (2024) · Transplantation · doi:10.1097/tp.0000000000005240 · Cited by 12
Self-citation
Hepatocellular carcinoma systemic treatment update: From early to advanced stage
Teng, W., Wu, T.-C., & Lin, S. (2024) · Biomedical Journal · doi:10.1016/j.bj.2024.100815 · Cited by 14
Oxaliplatin induces pyroptosis in hepatoma cells and enhances antitumor immunity against hepatocellular carcinoma
Deng, M., Zhao, R., Zou, H., Guan, R., Wang, J., Lee, C. M., He, B., Zhou, J., Li, S., Wei, W., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-024-02908-z · Cited by 12
“Clinical survival has improved in patients with HCC treated with tyrosine kinase inhibitors and immune checkpoint inhibitors [4 – 6].”
Precision oncology: The role of minimally-invasive ablation therapy in the management of solid organ tumors
Fazlollahi, F., & Makary, M. S. (2025) · World Journal of Radiology · doi:10.4329/wjr.v17.i1.98618 · Cited by 12
Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study
Lee, S., Yang, S., Tsai, P., Huang, C., Chen, C.-Y., Hung, C., Chen, C.-H., Tai, C., Cheng, P., Kuo, H., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.1015 · Cited by 12
International Validation and Refinement of Oncological Borderline Resectability Criteria for Hepatocellular Carcinoma Using Tumor Burden Score to Predict Survival
Akabane, M., Kawashima, J., Altaf, A., Woldesenbet, S., Cauchy, F., Aucejo, F., Popescu, I., Kitago, M., Martel, G., Ratti, F., et al. (2025) · Annals of Surgery Open · doi:10.1097/as9.0000000000000557 · Cited by 12
“13,14 Although some treatment guidelines have updated recommendations for systemic therapy, 2,15,16 there is still no clear consensus on the role of surgery in the multidisciplinary treatment of advanced HCC.”
Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma
Kodama, Y., Ueshima, K., Moriguchi, M., Inaba, Y., Yamashita, T., Iwamoto, H., Ueno, M., Ogasawara, S., Kuzuya, T., Kodama, T., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13648-5 · Cited by 12
Characteristics and Survival Outcomes of Hepatocellular Carcinoma After the Fontan Operation
Rosenthal, B. E., Hoteit, M. A., Lluri, G., Haeffele, C. L., Daugherty, T. J., Krasuski, R. A., Serfas, J. D., de Freitas, R. A., Porlier, A., Lubert, A. M., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101646 · Cited by 12
Advances in transarterial chemoembolization for hepatocellular carcinoma: Integration with systemic therapies and emerging treatment strategies
Sutanto, H., Adytia, G. J., Elisa, E., & Maimunah, U. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2025.04.004 · Cited by 12
“3,9 Locoregional therapies, such as transarterial chemoembolization (TACE), are cornerstone treatments for HCC, particularly for intermediate-stagediseaseasde ﬁ nedbytheBarcelonaClinicLiverCancer (BCLC) staging system [Table 1; Figure.”
Multi-omic analysis reveals a CAF-stemness-governed classification in HCC liver transplant recipients beyond the Milan criteria
Ling, S., Yu, J.-J., Zhan, Q., Gao, M., Liu, P., Wu, Y., Zhang, L., Shan, Q., Liu, H., Wang, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59745-8 · Cited by 12
Histopathologic Response and Oncologic Outcomes after Segmental and Subsegmental Transarterial Chemoembolization and Radioembolization for Hepatocellular Carcinoma
Sher, A., Todd, R., Shilo, D., Garcia-Reyes, K., Bishay, V. L., Patel, R. I., Patel, R. S., Fischman, A. M., Nowakowski, F., Lookstein, R., et al. (2025) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2025.05.009 · Cited by 12
Transarterial chemoembolization combined with intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: a phase 2 study
Mu, M.-Y., Chen, Z.-X., Cao, Y.-Z., Fu, X., Qiu, L.-J., Qi, H., & Gao, F. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217851 · Cited by 14
Cost-effectiveness analysis of artificial intelligence (AI) in earlier detection of liver lesions in cirrhotic patients at risk of hepatocellular carcinoma in Italy
Maas, L., Contreras-Meca, C., Ghezzo, S., Belmans, F., Corsi, A., Cant, J., Vos, W. G., Bobowicz, M., Rygusik, M., Łaski, D., et al. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2525006 · Cited by 12
“Once diagnosed with HCC, care was based on the Barcelona Clinic Liver Cancer (BCLC) staging sys-tem 17 that classifies HCC based on tumor characteristics and liver function.”
Self-citation
The unwell patient with advanced chronic liver disease: when to use each score?
Moore, O., Ma, W., Read, S. A., George, J., & Ahlenstiel, G. (2025) · BMC Medicine · doi:10.1186/s12916-025-04185-w · Cited by 12
“Integration of the CPS, as a measure of compensation status of ACLD, helps refine the Barcelona Clinic Liver Cancer (BCLC) strategy for treatment selection in HCC[15].”
Influential
Paraneoplastic Anti-Tif1-gamma Autoantibody-positive Dermatomyositis as Clinical Presentation of Hepatocellular Carcinoma Recurrence
Ferronato, M., Lalanne, C., Quarneti, C., Cevolani, M., Ricci, C., Granito, A., Muratori, L., & Lenzi, M. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00573 · Cited by 12
Mesoporous Nanoparticles for Diagnosis and Treatment of Liver Cancer in the Era of Precise Medicine
Wu, H., Wang, M.-D., Zhu, J., Li, Z., Wang, W., Gu, L., Shen, F., & Yang, T. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091760 · Cited by 12
Hepatectomy versus sorafenib for advanced hepatocellular carcinoma with macroscopic portal vein tumor thrombus: A bi‐institutional propensity‐matched cohort study
Komatsu, S., Ueshima, K., Kido, M., Kuramitsu, K., Tsugawa, D., Yanagimoto, H., Toyama, H., Ku, Y., Kudo, M., & Fukumoto, T. (2022) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.1236 · Cited by 12
A Novel Gene Signature Associated with Inflammatory Responses and Immune Status Assists in Prognosis and Intervention for Patients with HCC
Lu, G., Du, R., Feng, B., Wang, J., Zhang, F., Pei, J., Wang, Y., & Shang, Y. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s390113 · Cited by 11
Hepatocellular Carcinoma: Current Therapeutic Algorithm for Localized and Advanced Disease
Jose, A., Bavetta, M. G., Martinelli, E., Bronte, F., Giunta, E. F., & Manu, K. A. (2022) · Journal of Oncology · doi:10.1155/2022/3817724 · Cited by 12
“In these, atezolizumab/ bevacizumab or durvalumab/tremelimumab (sorafenib, lenvatinib or durvalumab if unavailable) indicate as frst-line treatment; second-line treatment with regorafenib or cabozantinib, ramucirumab (after treatment with sorafenib); a third line is represented by cabozantinib [103].”
BackgroundInfluential
Niclosamide Revitalizes Sorafenib through Insulin-like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma
Peng, S.-W., Ngo, M.-H. T., Kuo, Y., Teng, M.-H., Guo, C., Lai, H.-C., Chang, T., & Huang, Y. (2023) · Cancers · doi:10.3390/cancers15030931 · Cited by 13
“For advanced-stage HCC for which curative local therapies are infeasible, systemic pharmacological therapy is the mainstay of treatment [4].”
Background
Transarterial Chemoembolization with Anthracyclines-Loaded Polyethylene Glycol Drug Eluting Microspheres for the Treatment of Hepatocellular Carcinoma: A Pooled Multicentric Analysis of Survival in 580 Patients
Gomes, F. V., de Baère, T., Verset, G., Coimbra, É., Felice, G. A. T., Malagari, K. S., & Bruix, J. (2023) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-023-03362-9 · Cited by 12
“with our results, the expected OS in patients in the BCLC B stage was increasing in the last years and may now exceed 30 months [2].”
BackgroundResultSelf-citation
Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Yang, X., Deng, H., Sun, Y.-Y., Zhang, Y., Lu, Y., Xu, G., & Huang, X. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s399135 · Cited by 12
“Hepatocellular carcinoma (HCC) is the sixth most common type of cancer and the third leading cause of cancer-related deaths worldwide.1 Surgical resection and liver transplantation are potential radical treatments for HCC.”
BackgroundInfluential
The Role of Ablative Techniques in the Management of Hepatocellular Carcinoma: Indications and Outcomes
Koza, A., Bhogal, R. H., Fotiadis, N., & Mavroeidis, V. K. (2023) · Biomedicines · doi:10.3390/biomedicines11041062 · Cited by 12
“In patients with nodules not amenable to ablation due to the associated risk of adjacent organ damage or unsuitable location of the nodule, laparoscopic/robotic resection has provided an option where feasible, being less invasive and, thus, more suitable in patients who would otherwise be suboptimal candidates for an…”
BackgroundMethodInfluential
Adjuvant TACE may not improve recurrence-free or overall survival in HCC patients with low risk of recurrence after hepatectomy
Feng, L.-H., Zhu, Y.-Y., Zhou, J., Wang, M., Xu, W., Zhang, T., Mao, A., Cong, W., Dong, H. F., & Wang, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1104492 · Cited by 12
“02 or macrovascular invasions or satellites; (3) patients with extrahepatic metastasis; (4) a previous history of treatment of malignancy; (5) recurrence before or at adjuvant TACE; (6) perioperative mortality; and (6) incomplete data.”
Background
Cell-Free DNA as a Surveillance Tool for Hepatocellular Carcinoma Patients after Liver Transplant
Manzi, J. L. L., Hoff, C. O., Ferreira, R., Glehn-Ponsirenas, R., Selvaggi, G., Tekin, A., O’Brien, C., Feun, L. G., Vianna, R., & Abreu, P. (2023) · Cancers · doi:10.3390/cancers15123165 · Cited by 13
“Patients classified as B may also be referred to transplantation when using “extended liver-transplant criteria” according to the institution’s criteria, usually related to minor increases in the number or size of the tumors [14,17–19], but are more commonly directed towards other treatments, such as transarterial che…”
Method
Development and validation of a nomogram to predict the recurrence of hepatocellular carcinoma patients with dynamic changes in AFP undergoing locoregional treatments
Sun, Y., Xiong, Y., Wang, Q., Qiao, W., Zhang, H., & Zhang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1206345 · Cited by 12
Preoperative transarterial chemoembolization (TACE) + liver resection versus upfront liver resection for large hepatocellular carcinoma (≥5 cm): a systematic review and meta-analysis
Chan, K. S., Tay, W. X., Cheo, F. Y., & Shelat, V. G. (2023) · Acta chirurgica Belgica · doi:10.1080/00015458.2023.2256539 · Cited by 12
“The updated BCLC 2022 classification system recommends TACE as first-line potentially curative treatment for BCLC-B HCC with preserved portal flow [5,34,35].”
Method
LncRNA SLC1A5-AS/MZF1/ASCT2 Axis Contributes to Malignant Progression of Hepatocellular Carcinoma
Jiang, J., Dong, W., Zhang, W., Wang, Q., Wang, R., Wang, J., Wu, H., Dong, H., Zhao, R. C., Wang, J., et al. (2023) · Discovery Medicine · doi:10.24976/discov.med.202335179.96 · Cited by 12
Improved Survival Outcomes with Surgical Resection Compared to Ablative Therapy in Early-Stage HCC: A Large, Real-World, Propensity-Matched, Multi-Centre, Australian Cohort Study
Abdelmalak, J., Strasser, S. I., Ngu, N. L. Y., Dennis, C. V., Sinclair, M. J., Majumdar, A., Collins, K., Bateman, K., Dev, A. T., Abasszade, J. H., et al. (2023) · Cancers · doi:10.3390/cancers15245741 · Cited by 12
Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
Wagle, N. S., Park, S., Washburn, D. J., Ohsfeldt, R. L., Kum, H., & Singal, A. G. (2024) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-23-1236 · Cited by 12
Self-citation
No correlation between MASLD and poor outcome of Atezolizumab‐Bevacizumab therapy in patients with advanced HCC
Copil, F., Campani, C., Lequoy, M., Sultanik, P., Blaise, L., Wagner, M., Ganne‐Carrié, N., Ozenne, V., Thabut, D., Nault, J., et al. (2024) · Liver International · doi:10.1111/liv.15833 · Cited by 12
Predicting Survival Using Whole-Liver MRI Radiomics in Patients with Hepatocellular Carcinoma After TACE Refractoriness
Yang, C., Yang, H., Luo, Y., Li, F., Cong, T., Li, Y., Ye, F., & Li, X. (2024) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-024-03730-z · Cited by 12
“Meanwhile, the BCLC strategy recommends that treatment of HCC patients should be converted to systemic therapy (targeted therapy combined with immunotherapy) after TACE resistance [1]; however, the concept of TACE resistance is still controversial [6–8].”
Influential
Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
Sekiguchi, S., Tsuchiya, K., Yasui, Y., Inada, K., Kirino, S., Yamashita, K., Hayakawa, Y., Osawa, L., Higuchi, M., Takaura, K., et al. (2022) · Cancer Reports · doi:10.1002/cnr2.1613 · Cited by 12
Immunotherapy and Hepatocellular Cancer: Where Are We Now?
Valéry, M., Cervantes, B., Samaha, R., Gelli, M., Smolenschi, C., Fuerea, A. C., Tselikas, L., Prieux‐Klotz, C., Hollebecque, A., Boige, V., et al. (2022) · Cancers · doi:10.3390/cancers14184523 · Cited by 13
Predictive factors and prognostic models for Hepatic arterial infusion chemotherapy in Hepatocellular carcinoma: a comprehensive review
Lv, X., Zhang, P., Zhang, E., & Yang, S. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03765-7 · Cited by 11
“Locoregional therapy, targeted therapy, and immunotherapy have emerged as the primary treatments for advanced HCC [3].”
Immunotherapy resistance in MASLD-related hepatocellular carcinoma: special immune microenvironment and gut microbiota
Jin, J., Cheng, K., Chen, M., Liang, H., & Zhang, W. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.117394 · Cited by 13
Recent Advances in Ablative Therapies for Hepatocellular Carcinoma
Zahra, S. A., Nadeem, A., Kundu, A., Gibson, N., Haggaz, A., Sato, K. T., Lewandowski, R. J., & Gordon, A. C. (2025) · Cancers · doi:10.3390/cancers17193251 · Cited by 11
“In contrast to TARE, EBRT is not currently included in the 2022 BCLC guidelines as a standard treatment option [103].”
Impact of LEAP-012 and EMERALD-1 in the management of HCC
Singal, A. G., Garcia-Reyes, K., Kelley, R. K., & Kim, E. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101664 · Cited by 11
“Approximately 25% of patients had BCLC stage A HCC, 55-60% BCLC stage B HCC, and � 15% BCLC stage C HCC. Similarly, approximately 30% of patients in each arm had a HAP (hepatoma arterial-embolisation prognostic) score of A, � 35% had a score of B, 20-25% a score of C, and � 10% a score of D.”
InfluentialSelf-citation
Clinically significant portal hypertension (CSPH) on early-stage HCC following hepatectomy: What's the impact?
Xia, F., Huang, Z., Zhang, Q., Ndhlovu, E., Chen, X., Zhang, B., & Zhu, P. (2022) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2022.11.005 · Cited by 11
Combining Selective Internal Radiation Therapy with Immunotherapy in Treating Hepatocellular Carcinoma and Hepatic Colorectal Metastases: A Systematic Review
Ramdhani, K., Smits, M. L. J., Lam, M. G. E. H., & Braat, A. J. A. T. (2023) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2022.0071 · Cited by 11
“7,8 With mCRC, the current guidelines only consider SIRT as a possible treatment with patients failing the available chemotherapeutic agents.”
Secular Trends of Clinical Characteristics and Survival of Hepatocellular Carcinoma in Taiwan from 2011 to 2019
Kee, K., Chen, C., Hu, J., Huang, Y., Wang, T.-E., Chau, G., Chen, K.-H., Chen, Y., Lin, C., Hung, C., et al. (2022) · Viruses · doi:10.3390/v15010126 · Cited by 11
“The expected median survival year of the current BCLC treatment guidelines in 2022 is higher than in BCLC stages C and D [41].”
Understanding the Drawbacks of the Current Tumor Staging Systems: How to Improve?
Giacomelli, L., Sacco, R., Papa, S., & Carr, B. I. (2023) · Cancers · doi:10.3390/cancers15041242 · Cited by 11
BCL11B expression in hepatocellular carcinoma relates to chemosensitivity and clinical prognosis
Abé, H., Kamimura, K., Okuda, S., Watanabe, Y., Inoue, J., Aoyagi, Y., Wakai, T., Kominami, R., & Terai, S. (2023) · Cancer Medicine · doi:10.1002/cam4.6167 · Cited by 11

Authors: Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., Sangro, B., Singal, A. G., Vogel, A., Fuster, J., Ayuso, C., & Bruix, J.
Affiliations: Hospital Clínic de Barcelona (ES)
University of California, San Francisco (US)
University Medical Center of the Johannes Gutenberg University Mainz (DE)
University of Milan (IT)
Northwestern University (US)
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
The University of Texas Southwestern Medical Center (US)
Medizinische Hochschule Hannover (DE)
Corresponding author: Bruix, Jordi
ORCID: Reig, Maria
Forner, Alejandro
Rimola, Jordi
Burrel, Marta
Garcia-Criado, Ángeles
Kelley, Robin K.
Galle, Peter R.
Mazzaferro, Vincenzo
Salem, Riad
Sangro, Bruno
Singal, Amit G.
Vogel, Arndt
Fuster, Josep
Ayuso, Carmen
Bruix, Jordi
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2022-03
Volume: 76
Issue: 3
Pages: 681-693
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2021.11.018
PMC: PMC8866082
OpenAlex: W3213277274
Cited by: 4,319
References: 136
Citations by year: 2026: 684 · 2025: 1071 · 2024: 1166 · 2023: 962 · 2022: 424
FWCI: 83.72
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
eScholarship (California Digital Library) (submittedVersion)
Funders: Fundación Científica de la Asociación Española Contra el Cáncer (PI044031)
National Institutes of Health (R01 R01 MD012565, PI18/00768)
Horizon 2020 Framework Programme (952103)
Instituto de Salud Carlos III (AC16/00065, PI18/0358, PI15/00145, PI18/00542, PI19/00742, PI18/00768)
European Association for the Study of the Liver
Horizon 2020
Topics: Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Keywords: hepatocellular carcinoma, Barcelona Clinic Liver Cancer staging, outcome prediction, treatment guidelines, evidence-based clinical decision-making
MeSH terms: Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Staging, Prognosis, Severity of Illness Index

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks